158 related articles for article (PubMed ID: 35326598)
1. Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal Cancer.
Davis TB; Gupta S; Yang M; Pflieger L; Rajan M; Wang H; Thota R; Yeatman TJ; Pledger WJ
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326598
[TBL] [Abstract][Full Text] [Related]
2. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
Yang M; Davis TB; Pflieger L; Nebozhyn MV; Loboda A; Wang H; Schell MJ; Thota R; Pledger WJ; Yeatman TJ
BMC Cancer; 2022 Mar; 22(1):256. PubMed ID: 35272617
[TBL] [Abstract][Full Text] [Related]
3. Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.
Napolitano S; Matrone N; Muddassir AL; Martini G; Sorokin A; De Falco V; Giunta EF; Ciardiello D; Martinelli E; Belli V; Furia M; Kopetz S; Morgillo F; Ciardiello F; Troiani T
J Exp Clin Cancer Res; 2019 Dec; 38(1):492. PubMed ID: 31842958
[TBL] [Abstract][Full Text] [Related]
4. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
5. Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo.
Fan F; Ghosh S; Powell R; Roszik J; Park Y; Sobieski M; Sorokin A; Stephan C; Kopetz S; Ellis LM; Bhattacharya R
PLoS One; 2023; 18(3):e0281063. PubMed ID: 36952536
[TBL] [Abstract][Full Text] [Related]
6. Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target.
Fernandez ML; Dawson A; Hoenisch J; Kim H; Bamford S; Salamanca C; DiMattia G; Shepherd T; Cremona M; Hennessy B; Anderson S; Volik S; Collins CC; Huntsman DG; Carey MS
Cancer Cell Int; 2019; 19():10. PubMed ID: 30636931
[TBL] [Abstract][Full Text] [Related]
7. Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors.
Gu Y; Wei C; Chung M; Li H; Guo Z; Long M; Li Y; Wang W; Aimaier R; Li Q; Wang Z
Front Oncol; 2022; 12():910505. PubMed ID: 35965583
[TBL] [Abstract][Full Text] [Related]
8. MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer.
Xie M; Zheng H; Madan-Lala R; Dai W; Gimbrone NT; Chen Z; Kinose F; Blackstone SA; Smalley KSM; Cress WD; Haura EB; Rix U; Beg AA
Cancer Res; 2019 Nov; 79(22):5812-5825. PubMed ID: 31362929
[TBL] [Abstract][Full Text] [Related]
9. Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.
Fernández ML; DiMattia GE; Dawson A; Bamford S; Anderson S; Hennessy BT; Anglesio MS; Shepherd TG; Salamanca C; Hoenisch J; Tinker A; Huntsman DG; Carey MS
Am J Cancer Res; 2016; 6(10):2235-2251. PubMed ID: 27822414
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer.
Kurimchak AM; Shelton C; Herrera-Montávez C; Duncan KE; Chernoff J; Duncan JS
Mol Cancer Res; 2019 Aug; 17(8):1721-1734. PubMed ID: 31043489
[TBL] [Abstract][Full Text] [Related]
11. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Calizo A; Pratilas CA
Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
[TBL] [Abstract][Full Text] [Related]
12. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
13. Targeting SHP2 sensitizes differentiated thyroid carcinoma to the MEK inhibitor.
Zhi J; Yi J; Hou X; Wang W; Yang W; Hu L; Huang J; Guo S; Ruan X; Gao M; Zheng X
Am J Cancer Res; 2022; 12(1):247-264. PubMed ID: 35141016
[TBL] [Abstract][Full Text] [Related]
14. MEK in cancer and cancer therapy.
Neuzillet C; Tijeras-Raballand A; de Mestier L; Cros J; Faivre S; Raymond E
Pharmacol Ther; 2014 Feb; 141(2):160-71. PubMed ID: 24121058
[TBL] [Abstract][Full Text] [Related]
15. MEK inhibitor resistance mechanisms and recent developments in combination trials.
Kun E; Tsang YTM; Ng CW; Gershenson DM; Wong KK
Cancer Treat Rev; 2021 Jan; 92():102137. PubMed ID: 33340965
[TBL] [Abstract][Full Text] [Related]
16. HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL.
Carson R; Celtikci B; Fenning C; Javadi A; Crawford N; Carbonell LP; Lawler M; Longley DB; Johnston PG; Van Schaeybroeck S
Clin Cancer Res; 2015 Jul; 21(14):3230-3240. PubMed ID: 25813020
[TBL] [Abstract][Full Text] [Related]
17. Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma.
Verykiou S; Alexander M; Edwards N; Plummer R; Chaudhry B; Lovat PE; Hill DS
Br J Dermatol; 2019 Feb; 180(2):346-356. PubMed ID: 30339727
[TBL] [Abstract][Full Text] [Related]
18. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
[TBL] [Abstract][Full Text] [Related]
19. SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.
Fedele C; Ran H; Diskin B; Wei W; Jen J; Geer MJ; Araki K; Ozerdem U; Simeone DM; Miller G; Neel BG; Tang KH
Cancer Discov; 2018 Oct; 8(10):1237-1249. PubMed ID: 30045908
[TBL] [Abstract][Full Text] [Related]
20. New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging.
Brighton HE; Angus SP; Bo T; Roques J; Tagliatela AC; Darr DB; Karagoz K; Sciaky N; Gatza ML; Sharpless NE; Johnson GL; Bear JE
Cancer Res; 2018 Jan; 78(2):542-557. PubMed ID: 29180473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
